Enhancing Endogenous Opioid Concentrations as a Novel Treatment for Severe Pain
Clinical results unveiled at 17th annual industry summit on Pain Therapeutics this May in Central London.
London, United Kingdom, April 06, 2017 --(PR.com)-- SMi Group are delighted to welcome the expertise of Dr Tanja Ouimet, Head of Clinical Operations, at Pharmaleads, when she presents at the 17th annual Pain Therapeutics conference set to take place in Central London on 22nd and 23rd May 2017.
Created with an expert scientific advisory board from Zoetis, Cara Therapeutics and the University of Manchester, this year’s agenda will hone in the latest developments and innovations in effective and safe pain management.
When asked about what attendee’s will take away from her talk, Dr Ouimet said:
“My main role is to lead the development of our innovative pipeline for the treatment of severe acute and chronic pain. As a neuroscientist with over 20 years of experience in the field of peptide processing modulation, it is very exciting to be leading the clinical development of molecules that were designed, synthesized and characterized in our laboratories. What I hope to bring to the conference is the translation of these years of research to the development of much needed novel drugs for the treatment of pain and the new perspectives brought by our novel, enkephalin-powered, mechanism of action for pain relief.
“I will be presenting the latest clinical results obtained with our Dual Enkephalinase Inhibitor (DENKI) pipeline, with a focus on their actions on neuropathic pain, which open very promising new paths for the treatment of this unsatisfactorily treated illness.”
Enkephalins are highly potent opioids produced and released endogenously at the site of a painful stimulus. As they are rapidly degraded by two metalloproteases, aminopeptidase N (APN) and Neprilysin (NEP), the actions these opioid peptides are very short lived. Animal studies have shown that inhibiting the breakdown of enkephalins by inhibiting both NEP and APN produces significant analgesia. PL37 and PL265 are the first Dual ENKephalinase Inhibitors (DENKIs) to reach the clinic.
With a focus on enhancing endogenous opioid concentrations as a novel treatment for severe pain, highlights from the talk will include:
* Insight into MoA of the Dual ENKephalinase Inhibitors (DENKIs)
* Clinical results obtained with PL37
* Clinical development of PL265
The notable speaker line-up will also Nektar Pharmaceuticals, Cara Therapeutics, Centrexion Therapeutics, AstraZeneca, Zoetis, Janssen, Mundipharma, Amgen, Grunenthal and MSD USA.
A detailed conference agenda and full speaker line-up is available at http://www.pain-therapeutics.co.uk
A series of interviews with key speakers are also available to read in the event download centre at:
http://www.smi-online.co.uk/goto/2017pain-therapeutics.asp#tab_downloads
Pain Therapeutics 2017
22nd & 23rd May
Copthorne Tara Hotel, London, UK
Contact Information:
For media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Created with an expert scientific advisory board from Zoetis, Cara Therapeutics and the University of Manchester, this year’s agenda will hone in the latest developments and innovations in effective and safe pain management.
When asked about what attendee’s will take away from her talk, Dr Ouimet said:
“My main role is to lead the development of our innovative pipeline for the treatment of severe acute and chronic pain. As a neuroscientist with over 20 years of experience in the field of peptide processing modulation, it is very exciting to be leading the clinical development of molecules that were designed, synthesized and characterized in our laboratories. What I hope to bring to the conference is the translation of these years of research to the development of much needed novel drugs for the treatment of pain and the new perspectives brought by our novel, enkephalin-powered, mechanism of action for pain relief.
“I will be presenting the latest clinical results obtained with our Dual Enkephalinase Inhibitor (DENKI) pipeline, with a focus on their actions on neuropathic pain, which open very promising new paths for the treatment of this unsatisfactorily treated illness.”
Enkephalins are highly potent opioids produced and released endogenously at the site of a painful stimulus. As they are rapidly degraded by two metalloproteases, aminopeptidase N (APN) and Neprilysin (NEP), the actions these opioid peptides are very short lived. Animal studies have shown that inhibiting the breakdown of enkephalins by inhibiting both NEP and APN produces significant analgesia. PL37 and PL265 are the first Dual ENKephalinase Inhibitors (DENKIs) to reach the clinic.
With a focus on enhancing endogenous opioid concentrations as a novel treatment for severe pain, highlights from the talk will include:
* Insight into MoA of the Dual ENKephalinase Inhibitors (DENKIs)
* Clinical results obtained with PL37
* Clinical development of PL265
The notable speaker line-up will also Nektar Pharmaceuticals, Cara Therapeutics, Centrexion Therapeutics, AstraZeneca, Zoetis, Janssen, Mundipharma, Amgen, Grunenthal and MSD USA.
A detailed conference agenda and full speaker line-up is available at http://www.pain-therapeutics.co.uk
A series of interviews with key speakers are also available to read in the event download centre at:
http://www.smi-online.co.uk/goto/2017pain-therapeutics.asp#tab_downloads
Pain Therapeutics 2017
22nd & 23rd May
Copthorne Tara Hotel, London, UK
Contact Information:
For media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Contact
SMi Group
Teri Arri
+44 (0) 207 827 6068
http://www.pain-therapeutics.co.uk/prcom
Teri Arri
+44 (0) 207 827 6068
http://www.pain-therapeutics.co.uk/prcom
Contact
Categories